Cargando…
Imidazoles as Potential Anticancer Agents: An Update on Recent Studies
Nitrogen-containing heterocyclic rings are common structural components of marketed drugs. Among these heterocycles, imidazole/fused imidazole rings are present in a wide range of bioactive compounds. The unique properties of such structures, including high polarity and the ability to participate in...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307698/ https://www.ncbi.nlm.nih.gov/pubmed/34299488 http://dx.doi.org/10.3390/molecules26144213 |
_version_ | 1783728108632801280 |
---|---|
author | Sharma, Pankaj LaRosa, Chris Antwi, Janet Govindarajan, Rajgopal Werbovetz, Karl A. |
author_facet | Sharma, Pankaj LaRosa, Chris Antwi, Janet Govindarajan, Rajgopal Werbovetz, Karl A. |
author_sort | Sharma, Pankaj |
collection | PubMed |
description | Nitrogen-containing heterocyclic rings are common structural components of marketed drugs. Among these heterocycles, imidazole/fused imidazole rings are present in a wide range of bioactive compounds. The unique properties of such structures, including high polarity and the ability to participate in hydrogen bonding and coordination chemistry, allow them to interact with a wide range of biomolecules, and imidazole-/fused imidazole-containing compounds are reported to have a broad spectrum of biological activities. This review summarizes recent reports of imidazole/fused imidazole derivatives as anticancer agents appearing in the peer-reviewed literature from 2018 through 2020. Such molecules have been shown to modulate various targets, including microtubules, tyrosine and serine-threonine kinases, histone deacetylases, p53-Murine Double Minute 2 (MDM2) protein, poly (ADP-ribose) polymerase (PARP), G-quadraplexes, and other targets. Imidazole-containing compounds that display anticancer activity by unknown/undefined mechanisms are also described, as well as key features of structure-activity relationships. This review is intended to provide an overview of recent advances in imidazole-based anticancer drug discovery and development, as well as inspire the design and synthesis of new anticancer molecules. |
format | Online Article Text |
id | pubmed-8307698 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83076982021-07-25 Imidazoles as Potential Anticancer Agents: An Update on Recent Studies Sharma, Pankaj LaRosa, Chris Antwi, Janet Govindarajan, Rajgopal Werbovetz, Karl A. Molecules Review Nitrogen-containing heterocyclic rings are common structural components of marketed drugs. Among these heterocycles, imidazole/fused imidazole rings are present in a wide range of bioactive compounds. The unique properties of such structures, including high polarity and the ability to participate in hydrogen bonding and coordination chemistry, allow them to interact with a wide range of biomolecules, and imidazole-/fused imidazole-containing compounds are reported to have a broad spectrum of biological activities. This review summarizes recent reports of imidazole/fused imidazole derivatives as anticancer agents appearing in the peer-reviewed literature from 2018 through 2020. Such molecules have been shown to modulate various targets, including microtubules, tyrosine and serine-threonine kinases, histone deacetylases, p53-Murine Double Minute 2 (MDM2) protein, poly (ADP-ribose) polymerase (PARP), G-quadraplexes, and other targets. Imidazole-containing compounds that display anticancer activity by unknown/undefined mechanisms are also described, as well as key features of structure-activity relationships. This review is intended to provide an overview of recent advances in imidazole-based anticancer drug discovery and development, as well as inspire the design and synthesis of new anticancer molecules. MDPI 2021-07-11 /pmc/articles/PMC8307698/ /pubmed/34299488 http://dx.doi.org/10.3390/molecules26144213 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Sharma, Pankaj LaRosa, Chris Antwi, Janet Govindarajan, Rajgopal Werbovetz, Karl A. Imidazoles as Potential Anticancer Agents: An Update on Recent Studies |
title | Imidazoles as Potential Anticancer Agents: An Update on Recent Studies |
title_full | Imidazoles as Potential Anticancer Agents: An Update on Recent Studies |
title_fullStr | Imidazoles as Potential Anticancer Agents: An Update on Recent Studies |
title_full_unstemmed | Imidazoles as Potential Anticancer Agents: An Update on Recent Studies |
title_short | Imidazoles as Potential Anticancer Agents: An Update on Recent Studies |
title_sort | imidazoles as potential anticancer agents: an update on recent studies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307698/ https://www.ncbi.nlm.nih.gov/pubmed/34299488 http://dx.doi.org/10.3390/molecules26144213 |
work_keys_str_mv | AT sharmapankaj imidazolesaspotentialanticanceragentsanupdateonrecentstudies AT larosachris imidazolesaspotentialanticanceragentsanupdateonrecentstudies AT antwijanet imidazolesaspotentialanticanceragentsanupdateonrecentstudies AT govindarajanrajgopal imidazolesaspotentialanticanceragentsanupdateonrecentstudies AT werbovetzkarla imidazolesaspotentialanticanceragentsanupdateonrecentstudies |